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a b s t r a c t
Preclinical vaccineefﬁcacy studies aregenerally limited tocertain readoutparameters suchasassessment
of virus titers in swabs and organs, clinical signs, serum antibody titers, and pathological changes. These
parameters are not always routinely applied and not always scheduled in a logical standardized way. We
used computed tomography (CT) imaging as additional and novel read out parameter in a vaccine efﬁcacy
study by quantifying alterations in aerated lung volumes in ferrets challenged with the 2009 pandemic
A/H1N1 inﬂuenza virus.




The vaccinated group showed a daily gradual mean reduction with a maximum of 7.8%, whereas the
controls showed a maximum of 14.3% reduction. The pulmonary opacities evident on CT images were
most pronounced in the placebo-treated controls, and corresponded to signiﬁcantly increased relative
lung weights at necropsy.
This study shows that consecutive in vivo CT imaging allows for a day to day read out of vaccine efﬁcacy
by quantiﬁcation of altered aerated lung volumes.. Introduction
The ﬁeld of inﬂuenza virus research is in particular an area of
ew emerging viruses that requires rapid development of animal
odels needed for pathogenicity studies and assessment of ade-
uate vaccine candidates and antiviral therapies. This was recently
llustrated by the emergence of the 2009 pandemic A/H1N1
nﬂuenza virus (pH1N1) [1,2]. Ferrets are being implemented
xtensively in human inﬂuenza virus research. However, inﬂuenza
irus research is conducted in multiple separate laboratories all
ith their unique approach how to evaluate vaccine candidates
ithin the ferret challenge model. Substantial differences can
e found in all stages and aspects of challenge protocols, study
et-ups and read-out parameters. A spectrumof recently published
Abbreviations: ALV, aerated lung volume; RLW, relative lung weight.
∗ Corresponding author at: Department of Virology, Erasmus Medical Center, PO
ox 2040, 3000 CA Rotterdam, The Netherlands. Tel.: +31 10 704 4066,
ax: +31 10 704 4760.
E-mail address: a.osterhaus@erasmusmc.nl (A.D.M.E. Osterhaus).
264-410X © 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
ttp://dx.doi.org/10.1016/j.vaccine.2012.10.008© 2012 Elsevier Ltd. Open access under CC BY-NC-ND license.
[1,3–12] infection/challenge protocols showing this diversity is
listed in comparison in Table 1. In addition, obviously, different
inﬂuenza strains are used as challenge virus instigated by the
antigenic nature of the vaccine, or alternatively to evaluate efﬁcacy
to a heterologous inﬂuenza virus challenge. The routes of infection
being intranasal, intratracheal or through virus transmission from
experimentally infected and shedding ferrets show considerable
differences in implementation and outcomes [13]. Different viral
challenge doses are used, whether or not established in preceding
dose-ﬁnding studies. However, the challenge doses are pivotal
in the interpretation of a challenge outcome. Since, a too robust
challenge may prove, false negatively, a poor efﬁcacy of a human
vaccine candidate in the ferret model, and vice versa. Furthermore,
the duration of the challenge read out period varies, as well as the
types of samples collected and frequency of sampling. Often the
design of a challenge protocol is based on predeﬁned end points
and read outs, or may rely on results from historical experiments.Because of these variations in the assessment of vaccine efﬁ-
cacy, the comparison of the outcomes of vaccine studies may be
hampered, therefore a certain way of standardization could prove
useful by providing clarity.


































hRecently, we reported that CT-scanning allows quantiﬁcation
nd characterisation of inﬂuenza-induced pulmonary lesions in liv-
ng animals [11]. We  showed that the pulmonary ground-glass
pacities observed by CT scanning corresponded mainly to areas
f alveolar oedema, which is a major histological lesion in early
nﬂuenza-induced pneumonia and can be used to quantify the aer-
ted lung volume (ALV).
The  present study was performed to evaluate the immunogenic-
ty and protective efﬁcacy of an adjuvanted inactivated inﬂuenza
H1N1 vaccine for intranasal use in the ferret model. A group of
ix ferrets was intranasally immunised with this vaccine candi-
ate and compared to a second group of six ferrets that received
ntranasally administered PBS as placebo. These administrations
ere performed on study days 0, 21 and 42. All animals were subse-
uently intratracheally challenged with 106 median tissue culture
nfectious dose (TCID50) H1N1 A/The Netherlands/602/2009 virus
n study day 70. The animals were monitored for vaccine induced
erological and immunological responses and for infection related
linical and virological responses (data will be presented else-
here). As novel read out parameter CT-scanning was  performed 6
ays prior, and daily after, virus inoculation on all twelve ferrets to
onitor inﬂuenza induced lung damage by quantifying alterations
n the ALVs. The animals were sacriﬁced at 4 days post-inoculation
dpi) to evaluate pathological and virological parameters.
.  Material and methods
.1.  Animals
The ferrets (Mustela putorius furo) were females of 8 months
f age, seronegative for antibodies against current circulating
nﬂuenza viruses, and Aleutian disease virus. Housing and hand-
ing was performed under biosafety level (BSL)-3+ conditions
n negatively pressurized and high efﬁciency particulate air
HEPA)-ﬁltered biocontainment isolator units, approved by an
ndependent institutional laboratory animal ethics and welfare
ommittee. General injection anaesthesia (ketamine 8 mg/kg and
edetomidine-HCl 7.5 g/kg body weight) was applied during
andling and scanning.2.2. Immunisation
The animals (n = 6) were immunised three times with a 3 week
interval with an adjuvanted inactivated vaccine. 200 l of vac-
cine was  intranasally administered and divided equally over both
nostrils. The controls (n = 6) were similarly sham immunised with
200 l PBS intranasally (referred to as placebo).
2.3.  Challenge virus
All  animals were challenged, 4 weeks after the last immun-
isation, intratracheally with 106 median tissue culture infec-
tious dose (TCID50) of the 2009 pandemic inﬂuenza virus
A/Netherlands/602/2009 (pH1N1) in 3 ml  PBS, as described
previously [2,12,14]. The virus was routinely propagated in
MDCK cell cultures and infectious dose determined as described
previously[15], and titres calculated according to the method of
Spearman-Karber [16].
2.4. CT-scanning
All  animals were scanned on −6, 1, 2, 3, and 4 d.p.i. (see also
Table 1). A dual-source ultra fast CT-system (Somatom Deﬁnition
Flash, Siemens Healthcare) was used (temporal resolution: 0.075 s,
spatial resolution is 0.33 mm,  table speed of 458 mm/s: ferret tho-
rax acquisition time ≈ 0.22 s; enables accurate scanning of living
ferrets without the necessity of breath-holding, respiratory gat-
ing, or electrocardiogram (ECG)-triggering) as previously described
[11]. Brieﬂy, during scanning the ferrets were in dorsal recumbency
in a purposely built (Tecnilab-BMI) perspex biosafety container of
8.3 L capacity. The post-infectious reductions in aerated lung vol-
umes were measured from 3-dimensional CT reconstructs using
lower and upper thresholds in substance densities of −870 to −430
Hounsﬁeld units (HU).2.5.  Pathology
Following euthanasia by exsanguination all animals were sub-
mitted for necropsy. The lung lobes were inspected and lesions
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ere assessed while the lung was inﬂated. The trachea was  cut
t the level of the bifurcation and the lungs were weighed. The
elative lung weight was calculated as proportion of the body
eight on day of death (lung weight/body weight × 100).
Fig. 2. Changes in aerated lung volume after infection with H1N1
A/Netherlands/602/2009. The aerated lung volume was  calculated using lower and
upper thresholds in substance densities of −870 to −430 Hounsﬁeld units (HU) for
the analysis of 3D-reconstructions of the lung. The percentage change of aerated
lung  volume was calculated using the individual base line aerated lung volumes of
day 6 against the aerated lung volumes of the different days after infection. These
data  are expressed as mean ± SEM. Animals were intratracheally challenged with
106 TCID50 H1N1 A/The Netherlands/602/2009 on day 0.
3. Results and discussion
All  animals from both groups were scanned 6 days prior to
virus inoculation to deﬁne the uninfected base-line status of their
respiratory system. Consecutive in vivo imaging with CT scanning
showed that ferrets intranasally immunised with the vaccine can-
didate were largely protected against the appearance of pulmonary
ground-glass opacities, as is shown by means of transversal CT
images in Fig. 1 . The ALVs measured from 3D CT reconstructs like-
wise showed that the immunised ferrets were protected against
major alterations in ALV (group mean ALV ranging from 0.95 to
−7.8%) and did not show a temporal increase in ALV on 1 dpi,
which was observed in the placebo group (group mean ALV ran-
ging from 17.3 to −14.3%) (Fig. 2). This sudden and short increase
of 17.3% (Mann–Whitney test, two-tailed, P = 0.035) in the unpro-
tected placebo-treated animals may  result from a virally-induced
acute respiratory depression with compensatory hyperinﬂation.
A compensatory increase in respiratory tidal volume by means
of hyperinﬂation is a pathophysiological phenomenon known to
occur in respiratory viral infections [17,18]. However, CT scanning
could not discern possible emphysema due to ruptured alveoli as
cause of ALV increase. The relative change of ALVs on days 2, 3
and especially 4 after infection did not show signiﬁcant differences
between the two groups. One possible explanation is that over-
expansion of the thorax and lungs allows for increased alveolar
ﬂooding in excess of base line aeration resulting in approximately
unaltered ALVs between the two  groups. Another explanation is
that the inﬂamed and oedematous areas were aerated less than nor-
mal, but because the unaffected areas of lung were aerated more
Fig. 1. Consecutive transversal lung CT images after infection with H1N1
A/Netherlands/602/2009. Two columns of consecutive (top to bottom) transversal
lung  CT images of one representative immunised ferret (left) and one represen-
tative  placebo-treated ferret recorded in vivo compared with their gross aspect at
necropsy (bottom). At day 6 before infection, the lungs showed the clear aerated
baseline  condition, from 1 dpi with the new pandemic H1N1 inﬂuenza virus onwards
marked almost diffuse ground-glass opacities appear that show a gradual increase
with  a plateau on 3–4 dpi. The two photographs taken at necropsy on 4 dpi depict
the  ventral aspect of the lungs, with the hearts removed. The lungs of the placebo-
treated  animal (bottom right) show diffuse reddish consolidation indicative of acute
inﬂammation that essentially match the opacities on the CT images taken just before
necropsy; non-affected aerated lung tissue from the immunised animal is light pink
in colour (bottom left).










































[ig. 3. Relative lung weights. Mean relative lung weights (RLWs, related to body
eight;  ± SEM) at necropsy (4 dpi) for the immunised group versus the placebo-
reated  control group after infection with H1N1 A/Netherlands/602/2009.
han normal (hyperinﬂation or emphysema), the overall ALV values
emained approximately unaltered.
Nevertheless, these ALV proﬁles provide more detailed knowl-
dge about the inﬂuenza-induced respiratory disease development
han conﬁned data obtained from a single predeﬁned read out.
oreover, survival and recovery from challenge infection can be
ncluded in this set-up and with the opportunity to still measure the
evelopment of serum antibody responses upon challenge infec-
ion.
Upon necropsy, the relative lung weights (RLWs) of
he intranasally immunised ferrets was about 2-fold lower
Mann–Whitney, two-tailed, P < 0.0047) as compared to those of
he placebo-treated animals (Fig. 3), which is in agreement with
he absence of pulmonary ground-glass opacities. Usually, more
everely affected and inﬂamed lungs with increased amounts
f ﬂuid are heavier compared to normal or less affected lungs.
his translates within the ferret model in inﬂuenza research to
LWs ≤ 1.0 associated with non- to minimally affected lungs and
LWs > 1.0 associated with severe pulmonary inﬂammation with
edema [12,19,20].
In  conclusion, the implementation of consecutive CT imaging
nables repeated in vivo measurements of lung aeration as parame-
er to evaluate vaccine efﬁcacy in preclinical protocols. Consecutive
ay to day imaging overcomes the limitations entailed by necropsy
t a predeﬁned time point after infection, and the lung capacity can
e repeatedly quantiﬁed in real-time.
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